Earic Bonner, MD
Internal Medicine · Edenton, NCNPI 1548526411
Payments from drug & device makers
Across 412 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$764
- Lilly USA, LLC$659
- Boehringer Ingelheim$577
- Amgen$403
- plus $2K from 23 others
What the payments were for
- Consulting fees$1,26016%
- Food & beverage$6,56384%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,823 |
| Novo Nordisk | 102 | $1,323 |
| Sanofi-aventis U.S. LLC | 47 | $764 |
| Lilly USA, LLC | 37 | $659 |
| Boehringer Ingelheim | 33 | $577 |
| Amgen | 21 | $403 |
| Novartis | 20 | $304 |
| Pfizer | 17 | $283 |
| Johnson & Johnson | 22 | $254 |
| Merck | 17 | $234 |
| Abbott | 11 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $133 |
| Xeris Pharmaceuticals, Inc. | 7 | $129 |
| Grifols USA, LLC | 8 | $127 |
| GSK | 7 | $103 |
| Bayer | 6 | $94 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Corcept Therapeutics | 3 | $68 |
| Dexcom, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Neurocrine Biosciences, Inc. | 1 | $49 |
| AbbVie | 3 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Viiv Healthcare Company | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,823 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $131,255 |
| XareltoRivaroxaban | 159 | $124,266 |
| OzempicSemaglutide | 70 | $111,248 |
| JanuviaSitagliptin Phosphate | 94 | $76,864 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 79 | $74,604 |
| JardianceEmpagliflozin | 66 | $60,786 |
| TradjentaLinagliptin | 57 | $58,500 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $50,070 |
| TrulicityDulaglutide | 47 | $48,811 |
| RybelsusSemaglutide | 27 | $47,022 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $40,804 |
| FarxigaDapagliflozin Propanediol | 44 | $36,317 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 44 | $34,786 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $31,922 |
| LinzessLinaclotide | 43 | $31,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Glyxambi, Trijardy Xr | $577 | $206,256233 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,323 | $173,729108 claims |
| PfizerEliquis | $283 | $131,255151 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $234 | $129,570177 claims |
| Johnson & JohnsonXarelto | $254 | $124,266159 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $659 | $76,77375 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $764 | $74,60479 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $1,823 | $56,28599 claims |
| AbbVieLinzess, Synthroid | $39 | $35,58699 claims |
| GSKTrelegy Ellipta | $103 | $19,50129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Edenton
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.